CVE:ICO

iCo Therapeutics Competitors

C$0.10
0.00 (0.00 %)
(As of 03/19/2021)
Add
Compare
Today's Range
C$0.10
Now: C$0.11
C$0.11
50-Day Range
C$0.08
MA: C$0.10
C$0.13
52-Week Range
C$0.03
Now: C$0.11
C$0.16
Volume1.31 million shs
Average Volume3.16 million shs
Market CapitalizationC$18.27 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

iCo Therapeutics (CVE:ICO) Vs. QPT, CZO, CTX, KNE, GSD, and PAS

Should you be buying ICO stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to iCo Therapeutics, including Quest PharmaTech (QPT), Ceapro (CZO), Crescita Therapeutics (CTX), Kane Biotech (KNE), Devonian Health Group (GSD), and Pascal Biosciences (PAS).

Quest PharmaTech (CVE:QPT) and iCo Therapeutics (CVE:ICO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for Quest PharmaTech and iCo Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quest PharmaTech0000N/A
iCo Therapeutics0000N/A

Valuation & Earnings

This table compares Quest PharmaTech and iCo Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quest PharmaTechC$38,871.00474.71C$109.88 millionC$0.660.17
iCo TherapeuticsN/AN/AN/AC($0.01)-8.75

Quest PharmaTech has higher revenue and earnings than iCo Therapeutics. iCo Therapeutics is trading at a lower price-to-earnings ratio than Quest PharmaTech, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Quest PharmaTech and iCo Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quest PharmaTechN/AN/AN/A
iCo TherapeuticsN/AN/AN/A

Summary

Quest PharmaTech beats iCo Therapeutics on 3 of the 3 factors compared between the two stocks.

Ceapro (CVE:CZO) and iCo Therapeutics (CVE:ICO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk.

Valuation & Earnings

This table compares Ceapro and iCo Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CeaproC$16.14 million3.46C$2.56 millionC$0.0321.82
iCo TherapeuticsN/AN/AN/AC($0.01)-8.75

Ceapro has higher revenue and earnings than iCo Therapeutics. iCo Therapeutics is trading at a lower price-to-earnings ratio than Ceapro, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Ceapro and iCo Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ceapro0000N/A
iCo Therapeutics0000N/A

Profitability

This table compares Ceapro and iCo Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CeaproN/AN/AN/A
iCo TherapeuticsN/AN/AN/A

Summary

Ceapro beats iCo Therapeutics on 3 of the 3 factors compared between the two stocks.

Crescita Therapeutics (TSE:CTX) and iCo Therapeutics (CVE:ICO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.

Profitability

This table compares Crescita Therapeutics and iCo Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Crescita TherapeuticsN/AN/AN/A
iCo TherapeuticsN/AN/AN/A

Analyst Ratings

This is a summary of current ratings and price targets for Crescita Therapeutics and iCo Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Crescita Therapeutics0000N/A
iCo Therapeutics0000N/A

Earnings and Valuation

This table compares Crescita Therapeutics and iCo Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Crescita TherapeuticsC$15.64 million1.14C$41,296.00C$0.00430.00
iCo TherapeuticsN/AN/AN/AC($0.01)-8.75

Crescita Therapeutics has higher revenue and earnings than iCo Therapeutics. iCo Therapeutics is trading at a lower price-to-earnings ratio than Crescita Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Crescita Therapeutics beats iCo Therapeutics on 3 of the 3 factors compared between the two stocks.

iCo Therapeutics (CVE:ICO) and Kane Biotech (CVE:KNE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Profitability

This table compares iCo Therapeutics and Kane Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
iCo TherapeuticsN/AN/AN/A
Kane BiotechN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for iCo Therapeutics and Kane Biotech, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
iCo Therapeutics0000N/A
Kane Biotech0000N/A

Valuation & Earnings

This table compares iCo Therapeutics and Kane Biotech's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iCo TherapeuticsN/AN/AN/AC($0.01)-8.75
Kane BiotechC$1.34 million13.76C$-3,801,490.00C($0.04)-4.86

iCo Therapeutics has higher earnings, but lower revenue than Kane Biotech. iCo Therapeutics is trading at a lower price-to-earnings ratio than Kane Biotech, indicating that it is currently the more affordable of the two stocks.

Summary

Kane Biotech beats iCo Therapeutics on 2 of the 3 factors compared between the two stocks.

iCo Therapeutics (CVE:ICO) and Devonian Health Group (CVE:GSD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Profitability

This table compares iCo Therapeutics and Devonian Health Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
iCo TherapeuticsN/AN/AN/A
Devonian Health GroupN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for iCo Therapeutics and Devonian Health Group, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
iCo Therapeutics0000N/A
Devonian Health Group0000N/A

Valuation & Earnings

This table compares iCo Therapeutics and Devonian Health Group's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iCo TherapeuticsN/AN/AN/AC($0.01)-8.75
Devonian Health GroupC$1.59 million15.78C$-4,457,184.00C($0.05)-5.63

iCo Therapeutics has higher earnings, but lower revenue than Devonian Health Group. iCo Therapeutics is trading at a lower price-to-earnings ratio than Devonian Health Group, indicating that it is currently the more affordable of the two stocks.

Summary

Devonian Health Group beats iCo Therapeutics on 2 of the 3 factors compared between the two stocks.

iCo Therapeutics (CVE:ICO) and Pascal Biosciences (CVE:PAS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Profitability

This table compares iCo Therapeutics and Pascal Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
iCo TherapeuticsN/AN/AN/A
Pascal BiosciencesN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for iCo Therapeutics and Pascal Biosciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
iCo Therapeutics0000N/A
Pascal Biosciences0000N/A

Valuation & Earnings

This table compares iCo Therapeutics and Pascal Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iCo TherapeuticsN/AN/AN/AC($0.01)-8.75
Pascal BiosciencesN/AN/AN/AC($0.02)-4.09

iCo Therapeutics is trading at a lower price-to-earnings ratio than Pascal Biosciences, indicating that it is currently the more affordable of the two stocks.


iCo Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
QPT
Quest PharmaTech
0.8$0.11flatC$21.76 millionC$38,871.000.17High Trading Volume
CZO
Ceapro
0.7$0.72flatC$21.65 millionC$16.14 million21.82News Coverage
CTX
Crescita Therapeutics
0.6$0.86flatC$17.76 millionC$15.64 million430.00
KNE
Kane Biotech
0.4$0.17flatC$14.12 millionC$1.34 million-4.86
GSD
Devonian Health Group
0.5$0.27flatC$13.96 millionC$1.59 million-5.63Gap Up
PAS
Pascal Biosciences
0.6$0.09flatC$12.70 millionN/A-4.09
NSP
Naturally Splendid Enterprises
0.6$0.06flatC$11.06 millionC$2.03 million-1.40Gap Down
MPH
Medicure
0.7$1.60flatC$10.80 millionC$12.71 million-1.03Gap Down
BTI
Bioasis Technologies
0.7$0.39flatC$10.16 millionC$4.12 million35.45
HEM
Hemostemix
0.6$0.49flatC$9.07 millionN/A-2.92News Coverage
Gap Down
IBT
IBEX Technologies
0.7$0.36flatC$6.94 millionC$5.60 million6.57Gap Down
IOT
Innovotech
0.8$0.15flatC$6.52 millionC$1.04 million75.00Gap Up
BCT
BriaCell Therapeutics
0.5$6.40flatC$4.48 millionN/A-2.07High Trading Volume
Gap Down
RVV
Revive Therapeutics
0.5$0.08flatC$3.62 millionN/A-3.64High Trading Volume
News Coverage
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04flatC$1.54 millionN/A-0.30Upcoming Earnings
Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03flatC$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01flatC$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
Gap Down
HALO
Halozyme Therapeutics
1.7N/AN/AC$0.00C$267.59 million47.00
LTY
Liberty Biopharma
0.6$2.00flatC$0.00N/A-12.66Gap Down
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
News Coverage
SCYB
Scythian Biosciences
0.5$3.49flatC$0.00N/A0.00High Trading Volume
ABCN
VIVO Cannabis
0.6$1.32flatC$0.00N/A0.00Gap Down
VP
Vodis Pharmaceuticals
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.